Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 8;218(3):e20200839. doi: 10.1084/jem.20200839

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Deuse et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S1. — Cd47 protects MHC-deficient miECs and CD47 protects HLA-deficient hiECs from killing by NK cells and macrophages in vitro. (A–D) WT, B2m⁻^/⁻Ciita⁻^/⁻, and B2m⁻^/⁻Ciita⁻^/⁻ Cd47 tg miECs were challenged with syngeneic C57BL/6 NK cells (A), allogeneic BALB/c NK cells (B), syngeneic C57BL/6 macrophages (C), or allogeneic BALB/c macrophages (D). Where indicated, NK cells were stimulated with mouse IL-2 or IL-15. Graphs show mean ± SD and three independent replicates per group and time point; three different E:T ratios are shown. (E) B2m⁻^/⁻Ciita⁻^/⁻ miECs were incubated with syngeneic C57BL/6 macrophages treated with an activating anti-Pirb antibody (mean ± SD, three independent replicates per group and time point, and three different E:T ratios are shown). (F and G) WT, B2M⁻^/⁻CIITA⁻^/⁻, and B2M⁻^/⁻CIITA⁻^/⁻ CD47 tg hiECs were challenged with allogeneic human primary NK cells (F) or allogeneic human macrophages (G). Where indicated, NK cells were stimulated with IL-2 or IL-15. Where indicated, an agonist anti-LILRB1 antibody (clone GHI/75) was added to the assay. A specific blocking antibody against CD47 (clone B6.H12) or a blocking peptide against SIRPα was used in some assays. Graphs show mean ± SD and three independent replicates per group and time point; three different E:T ratios are shown. wt, wild-type.